Related Experiment Video

Updated: Jun 15, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Prevention of beta-cell destruction in autoimmune diabetes: current approaches and future prospects

Saikiran K Sedimbi1, Carani B Sanjeevi

  • 1Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Solna-17176, Stockholm, Sweden. saikiran.sedimbi@ki.se

Advances in Experimental Medicine and Biology
|March 11, 2010
PubMed

Insights

Type 1 diabetes (T1D) treatment aims to prevent pancreatic beta-cell destruction. This review covers antigen-based, antibody-based, and other therapies tested in animal models and human patients to preserve beta-cells.

Area of Science:

  • Immunology
  • Endocrinology
  • Cell Biology

Background:

  • Type 1 diabetes (T1D) is an autoimmune condition characterized by the progressive destruction of insulin-producing pancreatic beta-cells.
  • Preserving existing beta-cells and preventing further autoimmune assault is a key therapeutic goal in T1D management.

Purpose of the Study:

  • To review and categorize recent therapeutic strategies for Type 1 diabetes.
  • To evaluate approaches aimed at preventing or halting pancreatic beta-cell destruction in T1D.

Main Methods:

  • Literature review of current research in T1D therapies.
  • Categorization of therapeutic strategies into antigen-based, antibody-based, and other approaches.
  • Analysis of therapies tested in both animal models and human clinical trials.

Main Results:

  • Several therapeutic avenues are under investigation for T1D.
  • Antigen-based and antibody-based therapies show promise in preclinical and early clinical studies.
  • A range of other therapeutic modalities are also being explored.

Conclusions:

  • Preserving beta-cell function is crucial for managing Type 1 diabetes.
  • Diverse therapeutic strategies are being developed and tested to combat the autoimmune destruction of beta-cells.
  • Continued research into novel therapies is essential for improving T1D outcomes.

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...